Sintilimab Plus R-CHOP as the First-line Treatment in Patients With Diffuse Large B-Cell Lymphoma.
Clinical trial NCT04023916 · UNKNOWN
Trial details
- NCT number
- NCT04023916
- Sponsor
- Chinese Academy of Medical Sciences
- Status
- UNKNOWN
- Phase
- Phase 2
- Study type
- INTERVENTIONAL
- Start date
- 2019-12-01
- Primary completion
- 2020-07-30
- Enrollment
- 30
Track trials programmatically
Sponsors, conditions and status changes through the Atlas API.